Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipatasertib + paclitaxel
- Development stage
- Discontinued
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Ipatasertib + paclitaxel is a combination therapy that pairs ipatasertib, an AKT inhibitor, with paclitaxel, a chemotherapy drug. Ipatasertib works by inhibiting the AKT protein, which is often overactivated in cancer, particularly in tumors with PIK3CA/AKT1/PTEN alterations. This combination has been studied primarily for the treatment of triple-negative breast cancer (TNBC) and hormone receptor-positive, HER2-negative breast cancer.
02
Targets
TUBB (Tubulin (alpha and beta subunits))AKT2 (Rac-beta serine/threonine-protein kinase)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)
Beyond the preview
Go deeper on ipatasertib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipatasertib + paclitaxel.